Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Vyluma Inc. holds a company patent portfolio within the Biotechnology & Pharmaceuticals technology area. At present, the portfolio includes 1 pending office action. This action is assigned to 1 distinct art unit, indicating a specific and singular technical focus for the company's current patent applications. For practitioners, this concentration suggests that the company's legal strategy is deeply embedded in a specific regulatory or scientific niche within the broader biotechnology sector.
The prosecution is overseen by 1 distinct examiner, FAY, ZOHREH ALEMZADEH. This individual is the busiest examiner for the portfolio, with 1 busiest examiner pending action. Since the total count of pending office actions is 1, FAY, ZOHREH ALEMZADEH is the only examiner currently reviewing the company's active matters. This 1 to 1 relationship between the total workload and the busiest examiner's docket means that the company's immediate prosecution success rests entirely on the decisions of FAY, ZOHREH ALEMZADEH. This arrangement requires the applicant to focus their advocacy on the specific requirements of this 1 examiner, as there are no other active matters or examiners to provide a broader context for the portfolio's treatment.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| FAY, ZOHREH ALEMZADEH | 1 | 52.1% | -6.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18280778 | Multi-Dose Container for Ophthalmic Compositions | FAY, ZOHREH ALEMZADEH | 119d overdue |
| Art Unit | Apps |
|---|---|
| 1617 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18280778 | Multi-Dose Container for Ophthalmic Compositions | FAY, ZOHREH ALEMZADEH | 1617 | §103§112 | Non-Final OA | 119d overdue | Pending | Sep 07, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialVyluma Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Zohreh Alemzadeh Fay has the most, with 1 of Vyluma Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
